Perrigo Co.’s new chief executive officer is Uwe Rohrhoff, a 25-year veteran of the pharmaceutical industry.
The board of directors of the generic pharmaceuticals maker announced the appointment Monday morning, Jan. 8.
Rohrhoff has been named president and CEO, effective Jan. 15, 2018, following the retirement of John T. Hendrickson.
Hendrickson, who has worked for Perrigo since 1989, served as the company’s top executive since April of 2016. His plans to retire were announced in June.
Speaking of Rohrhoff, Perrigo Chairman Laurie Brlas stated in a press release, “He is an experienced, well-respected and successful CEO. Uwe brings a strong track record of operational excellence, strategic growth and healthcare supply chain management.”
Rohrhoff has worked since 1991 for Gerresheimer AG, a global manufacturer of pharmaceutical packaging products and medical devices for storage, dosage and safe administration of drugs. He has been CEO of that corporation since 2010.
Gerresheimer AG is a publicly-traded company that serves the pharmaceutical and healthcare industries. It is based on Dusseldorf, Germany.
“Uwe’s transformative strategic vision and focus on operational excellence enhanced the company’s leading market positions and created significant value for shareholders of approximately 225 percent in total shareholder return as CEO,” Brias said. “We are confident that his leadership style and industry, financial and operational expertise are the right fit for Perrigo.”
Commenting on the opportunities ahead for Perrigo in the press release, Rohrhoff said, “I am excited for the opportunity at Perrigo. I look forward to working with Perrigo’s experienced management team, who have been instrumental in positioning the company’s consumer OTC (over-the-counter) and prescription pharmaceutical businesses to capitalize on current trends in the market.”
He said he has long admired Perrigo and its mission “to deliver high-quality, affordable healthcare products that improve the lives of patients and families.”
Regarding Hendrickson, Brlas said, “We are grateful to John for his passionate leadership and contributions to the company over the past 28 years. John has been a trusted leader, a great colleague, and a friend to many, and we value his continued guidance as Uwe transitions into his new role.”
Perrigo Co. was founded in Allegan and the county continues to be the company’s largest center of operations. It has about 4,000 employees in West Michigan. The corporation’s global headquarters is now Dublin, Ireland.
By Al Jones
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).